Patents by Inventor Johannes Sam

Johannes Sam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP
    Publication number: 20240117049
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 11, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Juergen Peter BACHL, Alexander BUJOTZEK, Carina CANTRILL, Harald DUERR, Janine FAIGLE, Sabine IMHOF-JUNG, Christian KLEIN, Thomas KRAFT, Estelle MARRER-BERGER, Ekkehard MOESSNER, Laurene POUSSE, Petra RUEGER, Johannes SAM, Roland STAACK, Dietrich TUERCK, Pablo UMANA, Joerg ZIELONKA
  • COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
    Publication number: 20240109976
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1 BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Claudia Ferrera Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu
  • COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
    Publication number: 20240092856
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
  • PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS
    Publication number: 20230416412
    Abstract: The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of NACHT, LRR and PYD domains-containing protein 3 (NLRP3).
    Type: Application
    Filed: May 26, 2023
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Gabrielle LECLERCQ-COHEN, Johannes SAM, Nathalie STEINHOFF, Pablo UMAÑA
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20230416365
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 17, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES
    Publication number: 20230355754
    Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
  • Bispecific antigen binding molecules targeting OX40 and FAP
    Patent number: 11780919
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: October 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Juergen Peter Bachl, Alexander Bujotzek, Carina Cantrill, Harald Duerr, Janine Faigle, Sabine Imhof-Jung, Christian Klein, Thomas Kraft, Estelle Marrer-Berger, Ekkehard Moessner, Laurene Pousse, Petra Rueger, Johannes Sam, Roland Staack, Dietrich Tuerck, Pablo Umana, Joerg Zielonka
  • Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
    Patent number: 11718680
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 8, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Claudia Ferrara Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu
  • Tumor-targeted agonistic CD28 antigen binding molecules
    Patent number: 11608376
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti
  • Antibodies binding To HLA-A2/WT1
    Publication number: 20220411534
    Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 29, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
  • NOVEL ICOS ANTIBODIES AND TUMOR-TARGETED ANTIGEN BINDING MOLECULES COMPRISING THEM
    Publication number: 20220098305
    Abstract: The present invention relates to novel ICOS antibodies and tumor-targeted agonistic ICOS antigen binding molecules comprising them, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 31, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Tanja FAUTI, Jens FISCHER, Lucas HABEGGER, Christian KLEIN, Esther KOENIGSBERGER, Jens NIEWOEHNER, Johannes SAM, Pablo UMAÑA, Joerg ZIELONKA
  • BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP
    Publication number: 20220025046
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 31, 2021
    Publication date: January 27, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Juergen Peter BACHL, Alexander BUJOTZEK, Carina CANTRILL, Harald DUERR, Janine FAIGLE, Sabine IMHOF-JUNG, Christian KLEIN, Thomas KRAFT, Estelle MARRER-BERGER, Ekkehard MOESSNER, Laurene POUSSE, Petra RUEGER, Johannes SAM, Roland STAACK, Dietrich TUERCK, Pablo UMANA, Joerg ZIELONKA
  • Antibodies binding to HLA-A2/WT1
    Patent number: 11192957
    Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: December 7, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
  • THERAPEUTIC COMBINATION OF 4-1 BB AGONISTS WITH ANTI-CD20 ANTIBODIES
    Publication number: 20210163617
    Abstract: The present invention relates to combination therapies employing a 4-1BB agonist comprising at least one antigen binding domain capable of specific binding to tumor-associated antigen in combination with specific antibodies which bind human CD20 and the use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: September 10, 2020
    Publication date: June 3, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Christian KLEIN, Johannes SAM, Pablo UMANA, Wei XU
  • COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
    Publication number: 20210095002
    Abstract: The present invention relates to combination therapies employing 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, in combination with HER-2 targeting agents, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.
    Type: Application
    Filed: September 11, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Johannes SAM, Pablo UMANA
  • Combination therapy with targeted OX40 agonists
    Publication number: 20200392237
    Abstract: The present invention relates to combination therapies employing tumor targeted bispecific OX40 antibodies, in particular anti-FAP/anti-OX40 antibodies in combination with T-cell activating anti-CD3 bispecific antibodies specific for a tumor-associated antigen, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: April 28, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Sandra GRAU-RICHARDS, Christian KLEIN, Johannes SAM, Pablo UMANA, Sabine LANG, Maria AMANN, Mudita PINCHA
  • METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20200376119
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Application
    Filed: February 11, 2020
    Publication date: December 3, 2020
    Inventors: Marina BACAC, Sara COLOMBETTI, Christian KLEIN, Johannes SAM, Jose SARO, Pablo UMANA
  • COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
    Publication number: 20200325238
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: March 16, 2020
    Publication date: October 15, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Claudia FERRARA KOLLER, Christian KLEIN, Mario PERRO, Johannes SAM, Pablo UMAÑA, Wei XU
  • COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES
    Publication number: 20200306373
    Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20200199234
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI